Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Augmentation for Refractory Generalized Anxiety Disorder
NCT00113295Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in generalized anxiety disorder (GAD) comparing Paroxetine CR and Placebo with Quetiapine and continued paroxetine CR (2 arms). Primary endpoint: Hamilton Anxiety Scale at 18 weeks. Started Feb 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00113295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113295.